This seems to be a week for Big Pharma to do big things, and Novartis (NYSE: NVS ) and GlaxoSmithKline (NYSE: GSK )
are certainly doing their part. The two companies announced a series
of transactions that seem to offer "win-win" opportunities to clean up
and consolidate some non-core operations for both companies. Though it
seems like Glaxo is getting the better deal, there's arguably less risk
to the Novartis side of the transactions.
Read the full article here:
Is This a Good Deal for Novartis AG and GlaxoSmithKline plc?
No comments:
Post a Comment